NEW CELL & GENE THERAPY PLATFORM FOR SOLID TUMORS. GENE-DIRECTED ENZYME PRODRUG THERAPY (GDETP)

ERGANEO



28 Janvier 2022

Partager sur facebook Partager sur twitter Partager sur linkedin Partager sur google+

Fields

Biology / Medical

Sectors

Health

This so called « Gene-directed enzyme prodrug therapy (GDEPT) » consists in bringing an optimized gene - allowing to convert cyclophosphamide (CPA) into toxic metabolites 13 times more than native conversion - into the tumors, thanks to an efficient vector, mesenchymal stem cells (MSCs), and a specific (intra-arterial) administration. There, it eradicates the tumor and triggers a specific immune response, resulting in a vaccinating effect. POC in vivo have been established either in mice (treatment and rechallenge experiments), but also in an orthotopic model of hepatocarcinoma (VX2) in rabbits. Those last experiments confirmed breakthrough results, compared to Gold Standard (chemoembolization), either in terms of tumor & metastasis drastic reduction but also remission levels...

Applications:

  • Solid tumor treatments : hepatocarcinoma, colon, breast

Competitive advantages:

  • Increased therapeutic index thanks to a higher toxin concentration at tumor site only.
  • Strong direct by-stander effect (free diffusion of CPA toxic metabolites).
  • Specific and long-lasting anti-tumor specific immune response, which protects against recurrence and metastases.
  • In vivo proof of concept in two relevant animal models.

Keywords: Gene-directed enzyme prodrug therapy, Cyclophosphamide highly active metabolite conversion, New cancer treatment, Gene & cell therapy

Download the offer Download the offer

Newsletter